Literature DB >> 11829527

A system for small-molecule control of conditionally replication-competent adenoviral vectors.

Heung Chong1, Anja Ruchatz, Tim Clackson, Victor M Rivera, Richard G Vile.   

Abstract

Replication-competent adenoviral vectors are potentially far more efficient than replication-defective vectors. However, for reasons of safety, there is a need to restrict viral replication both spatially, by limiting replication to certain cell types, and temporally. To control replication temporally, we have developed a system, based on the small-molecule dimerizer rapamycin, for regulating the replication of adenoviral vectors. In this system, one adenoviral vector, AdC4, expresses transcription factors whose activity is regulated by the non-immunosuppressive rapamycin analog AP21967. A second vector, Ad(Z12-I-E1aE1b19k), contains E1 genes placed downstream of binding sites for the regulated transcription factor. Co-infection of several cell lines by the vector pair leads to dimerizer-dependent E1 expression and an increase in viral replication, as shown by Southern blots and replication assays. Furthermore, expression of a reporter gene from a replication-defective vector, Ad-GM-CSF, can be augmented by up to 18-fold by co-infection with the pair of conditionally replicating vectors in the presence of dimerizer. Similar results are obtained when the vectors are directly injected into subcutaneous HT1080 xenograft tumors in nude mice. We believe that vectors based on this principle will be a useful additional tool to enhance efficiency and safety of gene delivery for anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11829527     DOI: 10.1006/mthe.2002.0531

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  16 in total

1.  Inducible DNA-loop formation blocks transcriptional activation by an SV40 enhancer.

Authors:  Stefan Ludwig Ameres; Lars Drueppel; Klaus Pfleiderer; Andreas Schmidt; Wolfgang Hillen; Christian Berens
Journal:  EMBO J       Date:  2005-01-13       Impact factor: 11.598

2.  An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Authors:  Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

3.  Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors.

Authors:  Miwon Ahn; Aisha Gamble; Scott R Witting; Jack Magrisso; Sneha Surendran; Silvana Obici; Núria Morral
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

4.  Induction of apoptosis by rewiring the signal transduction of Epstein-Barr virus oncoprotein LMP1 toward caspase activation.

Authors:  Eudoxia G Hatzivassiliou; Theodore Tsichritzis; George Mosialos
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 5.  Mammalian synthetic biology: emerging medical applications.

Authors:  Zoltán Kis; Hugo Sant'Ana Pereira; Takayuki Homma; Ryan M Pedrigi; Rob Krams
Journal:  J R Soc Interface       Date:  2015-05-06       Impact factor: 4.118

6.  Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.

Authors:  Feng Yao; Nao Murakami; Oliver Bleiziffer; Pengwei Zhang; Natali V Akhrameyeva; Ximing Xu; Richard Brans
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

7.  Acute manipulation of phosphoinositide levels in cells.

Authors:  Belle Chang-Ileto; Samuel G Frere; Gilbert Di Paolo
Journal:  Methods Cell Biol       Date:  2012       Impact factor: 1.441

8.  Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.

Authors:  Alessandra Curioni Fontecedro; Verena Lutschg; Ossia Eichhoff; Reinhard Dummer; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2010-07-29       Impact factor: 4.099

9.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 10.  Gene therapy for gastric cancer: is it promising?

Authors:  Andreas P Sutter; Henry Fechner
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.